SETD2 and endometrial carcinoma: Third, although preclinical data has shown that SETD2 deficient cells have impaired MMR and HRR, we identified unimpaired HRR in endometrial carcinoma, colorectal adenocarcinoma, and stomach adenocarcinoma; this may be explained by possible synthetic lethality between impaired HRR and impaired MMR.